dextropropoxyphene Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 844 | 469-62-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
| 0.30 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.02 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 19.15 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 12 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 15 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.24 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 18 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 16, 1957 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 457.98 | 109.48 | 97 | 212 | 20937 | 2336839 |
| Toxicity to various agents | 278.22 | 109.48 | 71 | 238 | 32683 | 2325093 |
| Cardio-respiratory arrest | 210.90 | 109.48 | 45 | 264 | 9101 | 2348675 |
| Respiratory arrest | 192.06 | 109.48 | 39 | 270 | 6139 | 2351637 |
| Cardiac arrest | 178.45 | 109.48 | 43 | 266 | 14887 | 2342889 |
| Overdose | 118.28 | 109.48 | 33 | 276 | 19874 | 2337902 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N02AC04 | NERVOUS SYSTEM ANALGESICS OPIOIDS Diphenylpropylamine derivatives |
| ATC | N02AC54 | NERVOUS SYSTEM ANALGESICS OPIOIDS Diphenylpropylamine derivatives |
| ATC | N02AC74 | NERVOUS SYSTEM ANALGESICS OPIOIDS Diphenylpropylamine derivatives |
| FDA MoA | N0000175684 | Full Opioid Agonists |
| FDA EPC | N0000175690 | Opioid Agonist |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000701 | Analgesics, Opioid |
| CHEBI has role | CHEBI:35482 | opioid analgesic |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D009294 | Narcotics |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| CHEBI has role | CHEBI:55322 | mu-opioid receptor agonist |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pain | indication | 22253000 | |
| Necrotizing enterocolitis in fetus OR newborn | contraindication | 2707005 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Alcoholism | contraindication | 7200002 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Alcohol intoxication | contraindication | 25702006 | |
| Shock | contraindication | 27942005 | |
| Hypovolemia | contraindication | 28560003 | |
| Orthostatic hypotension | contraindication | 28651003 | |
| Hypercapnia | contraindication | 29596007 | |
| Depressive disorder | contraindication | 35489007 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Vitamin K deficiency | contraindication | 52675005 | DOID:11249 |
| Nasal polyp | contraindication | 52756005 | |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Substance abuse | contraindication | 66214007 | |
| Poisoning by acetaminophen | contraindication | 70273001 | |
| Agoraphobia | contraindication | 70691001 | DOID:593 |
| Factor II deficiency | contraindication | 73975000 | |
| Reye's syndrome | contraindication | 74351001 | DOID:14525 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
| Decreased respiratory function | contraindication | 80954004 | |
| Injury of head | contraindication | 82271004 | |
| Cor pulmonale | contraindication | 83291003 | DOID:8515 |
| Gout | contraindication | 90560007 | DOID:13189 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Hemophilia | contraindication | 90935002 | |
| Disorder of biliary tract | contraindication | 105997008 | DOID:9741 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Prolonged QT interval | contraindication | 111975006 | |
| von Willebrand disorder | contraindication | 128105004 | DOID:12531 |
| Seizure disorder | contraindication | 128613002 | |
| Prolonged PR interval | contraindication | 164947007 | |
| Obsessive-compulsive disorder | contraindication | 191736004 | DOID:10933 |
| Insomnia | contraindication | 193462001 | |
| Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
| Impaired renal function disorder | contraindication | 197663003 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Exacerbation of asthma | contraindication | 281239006 | |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Panic disorder | contraindication | 371631005 | DOID:594 |
| Hypoxia | contraindication | 389086002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Myocardial infarction in recovery phase | contraindication | 418044006 | |
| Central nervous system depression | contraindication | 418072004 | |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Acute erosive gastritis | contraindication | 444926003 | |
| Acute exacerbation of asthma | contraindication | 708038006 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.26 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Mu-type opioid receptor | GPCR | AGONIST | WOMBAT-PK | CHEMBL | |||||
| Glutamate receptor ionotropic, NMDA 3A | Ion channel | IC50 | 5.30 | WOMBAT-PK | |||||
| Sodium channel protein type 5 subunit alpha | Ion channel | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019915 | VUID |
| N0000148000 | NUI |
| C0033493 | UMLSCUI |
| D00482 | KEGG_DRUG |
| 38M219L1OJ | UNII |
| 26570-10-5 | SECONDARY_CAS_RN |
| 387042001 | SNOMEDCT_US |
| 117005003 | SNOMEDCT_US |
| 4019915 | VANDF |
| 8785 | RXNORM |
| d00360 | MMSL |
| 001574 | NDDF |
| DB00647 | DRUGBANK_ID |
| 740 | INN_ID |
| CHEBI:51173 | CHEBI |
| 7593 | IUPHAR_LIGAND_ID |
| CHEMBL1213351 | ChEMBL_ID |
| CHEMBL1237104 | ChEMBL_ID |
| D011431 | MESH_DESCRIPTOR_UI |
| CHEMBL3989716 | ChEMBL_ID |
| 10100 | PUBCHEM_CID |
| C084813 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 12634-537 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 16 sections |
| Propoxyphene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-198 | CAPSULE | 65 mg | ORAL | ANDA | 13 sections |
| Darvon-N | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-874 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 14 sections |
| Propoxyphene Napsylate and Acetaminophen | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-280 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 15 sections |
| Propoxyphene and Acetaminophen | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63874-201 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 17 sections |
| PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 67296-0104 | TABLET | 100 mg | ORAL | ANDA | 19 sections |
| PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 67296-0105 | TABLET | 100 mg | ORAL | ANDA | 19 sections |
| Propoxyphene Napsylate and Acetaminophen | HUMAN PRESCRIPTION DRUG LABEL | 2 | 67296-0378 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 16 sections |
| Propoxyphene and Acetaminophen | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68387-100 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 17 sections |